الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Albumin nanoparticles and QDs show improved drug tumor accumulation and strong fluorescence properties for tumor imaging.
However, premature drug release into circulation and high toxicity of QDs due to heavy metal leakage limit their applications.
Following this motif, we developed novel cancer nano-theranostics consisting of biocompatible BSA backbone with coupled CdTe QDs and mannose groups to enhance tumor targeting.
The chemotherapeutic drug pemetrexed (PMT) was conjugated via tumor-cleavable bond to the albumin backbone for tumor site-specific release.
In combination, resveratrol (RSV) was physically encapsulated into BSA NPs either free or preformulated as phospholipid complex.
Albumin-QD theranostics showed good hemocompatibility and excellent serum stability in addition to enhanced cytotoxicity to breast cancer cells.
They displayed high fluorescence quantum yield, and excellent imaging capacity enabling tracing of their intracellular uptake into cancer cells as observed by confocal laser scanning microscopy.
The nanocarriers demonstrated superior anti-tumor effects in vivo including reduction in tumor volume, increased apoptosis, as well as inhibition of angiogenesis in addition to non-immunogenic response.
Moreover, in vivo bioimaging tests demonstrated excellent tumor-specific accumulation of targeted nanocarriers via QDs mediated fluorescence.
Thus, we believe this multifunctional mannosylated albumin-QD nanoplatform could be a potential nanotheranostic for bioimaging and targeted therapy of breast cancer.